Azurity Pharmaceuticals Acquires Covis Pharma

ATHAGORAS Group Acquires CSO Pharma Consulting GmbH

November 18, 2024

Healthcare Services

ATHAGORAS Group has acquired CSO Pharma Consulting GmbH to expand and internationalize its pharmacovigilance, medical affairs, quality management and GDP consulting capabilities across the pharma and healthcare sectors. The deal adds a specialized provider of PV and regulatory support to ATHAGORAS' life‑sciences services platform while CSO retains focus on organic growth and continuity for clients and employees.

Covis Acquires Global Rights to Eklira and Duaklir from AstraZeneca

January 5, 2022

Pharmaceuticals

Covis Pharma Group completed the acquisition of global rights to the respiratory medicines Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) from AstraZeneca for an upfront payment of $270 million, with additional payments tied to ongoing development costs. Covis also entered an exclusive promotion and distribution agreement with Novartis Pharmaceuticals Canada to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada, strengthening Covis' respiratory platform and market position.

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

September 24, 2021

Pharmaceuticals

Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

Covis Group Acquires AMAG Pharmaceuticals

November 16, 2020

Pharmaceuticals

Covis Group S.à r.l. completed a cash tender offer and merger to acquire AMAG Pharmaceuticals, Inc. for $13.75 per share, taking AMAG private and delisting its NASDAQ shares. The acquisition adds AMAG’s marketed products (including Feraheme and Makena) and development-stage assets in women’s health and hematology/oncology to Covis’ specialty pharma portfolio, supported by financing from Capital One and investment funds managed by HPS Investment Partners.

Apollo Funds to Acquire Covis Pharma from Cerberus

February 6, 2020

Pharmaceuticals

Funds managed by affiliates of Apollo Global Management have agreed to acquire Covis Pharma BV from an affiliate of Cerberus Capital Management. Terms were not disclosed; the transaction is expected to close by the end of Q1 2020 and aims to accelerate Covis's global expansion and build out its respiratory and specialty pharma franchises.

CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals

June 12, 2019

Pharmaceuticals

CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.